Jodie Morrison
Venture Partner at Atlas Venture
United States
Overview
Work Experience
Board Member
2024 - Current
Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.
Raised $419,300,000.00 from Eli Lilly.
CEO and Board Member
2022
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Raised $148,000,000.00 from OrbiMed, Homology Medicines, Bristol-Myers Squibb, Atlas Venture, Agent Capital, Acorn Bioventures, Sanofi Ventures, The CU Healthcare Innovation Fund, Abingworth and OUP (Osage University Partners).
CEO Forum, Founder
2020
Founder of The CEO Forum. Founded to help biotech CEOs manage their companies through the COVID-19 crisis and continued in an effort to provide a community for best practices for CEOs around challenges like the SVB banking crisis, global risks to CROs, and the reintegration of the workforce in a new hybrid world.
Member Board of Directors
2021
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.
Venture Partner/Advisor
2021
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Principal and Founder
2017
Providing independent consulting services to venture capital and Biotech/Pharmaceutical companies.
Chair Of The Board Of Directors
2020 - 2023
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Raised $259,000,001.00 from Pfizer Venture Investments.
Member Board Of Directors
2017 - 2023
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.
Raised $256,212,894.00 from Nantahala Capital Management and Bios Partners.
Chief Executive Officer
2019 - 2021
Through the successful sale to Novartis.
Member Board of Directors
2016 - 2020
Joined Keryx BOD in 2016. Member of R&D Committee and Audit Committee.
Interim CEO
2018 - 2018